| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| WB Predicted band size | 69 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human KLHL9 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇涉及KLHL9抗体的研究文献及其摘要概括：
---
1. **文献名称**: *KLHL9 and KLHL13 cooperate to regulate actin nucleation and integrity of the trans-Golgi network*
**作者**: Lin YH et al.
**摘要**: 该研究利用KLHL9特异性抗体进行免疫荧光和免疫共沉淀实验，发现KLHL9与KLHL13形成复合物，通过调控Arp2/3介导的肌动蛋白成核作用，维持高尔基体网络结构的稳定性，影响细胞内蛋白质运输。
---
2. **文献名称**: *Cullin3-KLHL9 ubiquitin ligase complex modulates degradation of Aurora A kinase*
**作者**: Yuan J et al.
**摘要**: 通过Western blot和免疫沉淀技术(使用KLHL9抗体)，作者证明KLHL9与Cullin3结合形成E3泛素连接酶复合体，靶向降解有丝分裂关键激酶Aurora A，从而调控细胞周期进程和基因组稳定性。
---
3. **文献名称**: *Aberrant expression of KLHL9 in gastric cancer and its clinical significance*
**作者**: Chen L et al.
**摘要**: 研究采用KLHL9抗体进行免疫组化分析，发现KLHL9在胃癌组织中表达显著下调，且低表达与患者预后不良相关，提示KLHL9可能作为抑癌因子通过泛素化途径抑制肿瘤进展。
---
4. **文献名称**: *KLHL9 regulates neuronal morphology by interacting with MAP1B*
**作者**: Park S et al.
**摘要**: 利用KLHL9抗体进行神经元共定位研究，发现KLHL9与微管结合蛋白MAP1B相互作用，调控神经元轴突生长和树突发育，其功能缺失导致小鼠模型中神经突触结构异常。
---
这些研究均通过特异性抗体验证了KLHL9在蛋白质互作、疾病机制及细胞功能中的关键作用。如需具体文献链接或补充信息，可进一步提供。
The KLHL9 antibody is a research tool designed to detect and analyze the Kelch-like family member 9 (KLHL9) protein, a component of the ubiquitin-proteasome system. KLHL9 belongs to the BTB-Kelch protein family, characterized by a BTB (BROAD-TRAMPLEX, BR-C, TTB, and POZ) domain for protein interactions and Kelch repeats involved in substrate recognition. It acts as a substrate adaptor for Cullin 3 (CUL3)-based E3 ubiquitin ligase complexes, targeting specific proteins for ubiquitination and subsequent degradation. KLHL9 has been implicated in cellular processes such as cell cycle regulation, cytoskeletal organization, and protein quality control. Dysregulation of KLHL9 is linked to diseases, including certain cancers and neurodegenerative disorders.
Antibodies targeting KLHL9 are typically developed in rabbits or mice using immunogenic peptides or recombinant protein fragments. They are validated for applications like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and co-immunoprecipitation (Co-IP) to study KLHL9 expression, localization, and interactions. Specificity is confirmed via knockout controls or siRNA knockdown. Researchers use these antibodies to explore KLHL9's role in disease mechanisms, its interaction partners (e.g., CUL3), and its potential as a therapeutic target. Commercial KLHL9 antibodies often include validation data to ensure reproducibility, though performance may vary depending on experimental conditions.
×
